Global Cryoablation Market 2020-2026
在預測期內，全球冷凍消融市場預計將以 11.2% 的驚人復合年增長率增長。推動冷凍消融市場增長的主要因素包括癌症等慢性病的患病率增加和生活方式的改變。此外，微創技術的接受和研發投入的增加是推動市場增長的其他主要因素。這種治療的新應用將為冷凍消融市場帶來巨大機遇。
冷凍手術用於治療多種類型的癌症和一些癌前病變。除了冷凍手術、前列腺和肝臟腫瘤，冷凍消融術還可以有效治療視網膜母細胞瘤、早期皮膚癌、光化性角化病和宮頸癌。治療基於 20-40 秒應用（根據需要多次）可重新填充的金屬探針，該探針被電加熱至約 100度C，這對於上皮和間質破壞最重要。..冷凍消融由各種醫療保健專業人員提供，包括初級醫療保健，並且通常在沒有麻醉的情況下進行。冷凍消融還用於治療某些類型骨骼的低度癌性和非癌性腫瘤。與大型手術相比，冷凍消融有助於降低關節損傷的風險並減少排除的需要。當皮膚損傷很小且有限時，這種療法也用於治療與愛滋病相關的卡波西肉瘤。
然而，某些因素，例如冷凍治療中使用的製冷劑氣體（N2O 或 CO2），正在影響冷凍消融市場的增長。氣體容器運輸起來又重又笨重，可能會導致新興國家和低收入國家 (LMIC) 出現供應問題。補充冷凍氣體可能很昂貴。此外，2020 年 7 月，Healio 宣佈美國 FDA 將擴大冷凍消融技術用於治療頭、腎、肝和頸部腫瘤的批准。 2020 年 1 月，IceCure Medical Ltd. 宣佈美國 FDA 批准冷凍消融技術。獲得批准後，該公司將能夠銷售用於治療肝臟、腎臟、耳朵、鼻子和喉嚨（耳鼻喉科）的癌性和非威脅性腫瘤的解決方案。
全球冷凍消融市場根據使用情況和最終用戶進行劃分。根據用途，市場分為腫瘤學、心臟病學等。預計到 2020 年，腫瘤學領域將佔據冷凍消融市場的最大份額。由於癌症患病率上升、產品改進和政府對癌症研究的資金增加，以及新興國家越來越多地採用釔 90 心臟栓塞，市場正在增長。根據最終用戶，市場細分為醫院、診所和門診手術中心。
全球冷凍消融市場是根據對市場增長做出重大貢獻的地理區域進行分析的。市場報告包括北美（美國和加拿大）、歐洲（英國、德國、意大利、西班牙、法國和其他歐洲）、亞太地區（中國、日本、印度和其他亞太地區）和其他地區（RoW）。可以分為。據估計，北美是全球冷凍消融市場的主要地區。癌症患病率是區域市場增長的主要驅動力之一。在 2021 年至 2027 年的預測期內，亞太地區預計將成為增長最快的地區。
全球冷凍消融市場的領先企業包括 Medtronic Inc.、Boston Scientific Corp.、Johnson & Johnson Services, Inc.、AtriCure, Inc. 和 Cooper Surgical。為了在市場中生存，這些參與者採用了各種營銷策略，包括合併、收購、產品發佈、地域擴張和慈善事業。例如，2020 年 2 月，波士頓科學公司的 POLARx 冷凍消融系統獲得了 CE 標誌，該系統被指定用於治療陣發性心房顫動 (AF) 患者。百分比。
Global Cryoablation Market Size, Share & Trends Analysis Report By Application (Oncology, Cardiology, Others), and By End-User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), Forecast Period 2021-2027
The global cryoablation market is expected to grow at an impressive CAGR of 11.2% during the forecast period. The major factors that are augmenting the growth of the cryoablation market include an increase in the prevalence of chronic diseases such as cancer and changing lifestyles. In addition, the acceptance of minimally invasive technology and increasing investments in R&D are other major factors augmenting the market growth. The emerging application of this therapy will turn out to be a huge opportunity for the cryoablation market.
Cryosurgery is used to treat several types of cancer and some precancerous conditions. In addition to cryosurgery, prostate, and liver tumors, cryoablation can be an effective treatment for retinoblastoma, early-stage skin cancers, actinic keratosis, and cervical cancer. Treatment is based on a 20-40 second application (multiple if needed) of a refillable metallic probe that is electrically heated to approximately 100 °C, most important to epithelial and stromal destruction. Cryotherapy ablation is providing by a diversity of healthcare professionals, including primary healthcare workers, and typically performed without anesthesia. Cryosurgery is also used to treat some types of low-grade cancerous and noncancerous tumors of the bone. Cryoablation moderates the risk of joint damage while compared with more extensive surgery and helps reduce the need for exclusion. The treatment is also used to treat AIDS-related Kaposi sarcoma when the skin injuries are small and confined.
However, certain factors are affecting the growth of the cryoablation market such as refrigerant gas (N2O or CO2) that are used in cryotherapy the gas containers are heavy and bulky to transport and in the emerging and low-income countries (LMICs) may have supply issues. Refilling freezing gas can be costly. Moreover, in July 2020, Healio announced the US FDA expands clearance of cryoablation technology for the treatment of head, kidney, liver, and neck tumors. In January 2020, IceCure Medical Ltd. announced the US FDA approval for its cryoablation technology, the approval enables the Company to market its solution for the treatment of cancerous and non-threatening tumors of the liver, Kidney, Ear, Nose, and Throat (ENT).
The global cryoablation market is segmented based on application and end-user. Based on application, the market is segmented into oncology, cardiology, and others. The oncology segment is projected for the largest share of the cryoablation market in 2020. The market is growing due to the rising prevalence of cancer, product enhancements, and increasing government funding for cancer research. and the increasing adoption of Yttrium-90 cardioembolic agents in developing countries. Further, based on end-user, the market is sub-segmented into hospitals, clinics, and ambulatory surgical centers.
Global Cryoablation Market Share by Application, 2020 (%)
Source: OMR Global
The global cryoablation market is analyzed based on the geographical regions that are contributing significantly to the growth of the market. The market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific) and Rest of the World (RoW). North America is estimated to be the leading region in the global cryoablation market. The prevalence of cancer is one of the major factors driving the growth of the market in the region. The Asia-Pacific is estimated to be the fastest-growing region during the forecast period 2021-2027.
Global Cryoablation Market Growth, by Region 2021-2027
Source: OMR Global
Asia-Pacific to register considerable growth in the global cryoablation market
In Asia-Pacific, the cryoablation market is driven by various factors including an increased prevalence of cancer and cardiovascular disease and government funding on cancer research. China is expected to be one of the leading countries the due to rising prevalence of cardiac diseases such as heart stroke and the development of cardiovascular devices in the country.
Market Players Outlook
Key players of the global cryoablation market include Medtronic Inc., Boston Scientific Corp., Johnson & Johnson Services, Inc., AtriCure, Inc., and CooperSurgical. To survive in the market these players adopt different marketing strategies such as a merger, acquisitions, product launches, geographical expansion, charities so on. For instance, in February 2020, Boston Scientific Corp. received CE Mark for the POLARx Cryoablation System, which is designated for the treatment of patients with paroxysmal atrial fibrillation (AF), an intermittent form of AF which causes an irregular and often abnormally fast heart rate.
The Report Covers